Abstracts

Background and purpose Interferons (IFN), such as IFNα and IFNγ, are known to play a pivotal role for the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). These IFNs enhance the expression of mCD64. We recently have reported a tight correlation between mCD64 expression levels and SLE disease activity index (SLEDAI) (r=0.68, p<0.001) (Lupus 24(10):1076–80, 2015) and shown that mCD64 expression is a simple and useful biomarker for evaluating disease activity in SLE patients. Although neuropsychiatric manifestations are critical to the management of SLE, there have been no precise and convenient biomarkers assessing the activity of NPSLE. In this study, we investigated the utility of mCD64 expression as a biomarker for NPSLE.

Method mCD64 expression levels were assessed quantitatively by using flow cytometry in five patients with NPSLE. The mCD64 expression levels were compared with SLEDAI and other conventional SLE activity markers, such as anti-dsDNA antibody, complements and cerebrospinal fluid (CSF) IL-6.

Result The NPSLE events included three headaches, two aseptic meningitis and one acute confusion. At the active phase of these NPSLE events, mCD64 expressions were significantly enhanced at the median of 38,541 (range 31,693–73,287) molecules/cell compared to the treated inactive phase. Additionally, mCD64 expression was significantly higher in CSF IL-6 high (more than 4.3 pg/ml) group than the low group (p=0.011). The mCD64 expression levels were significantly decreased at the inactive phase of the NPSLE after treatment (p=0.027) shown in figure 1. The changes of mCD64 expression levels correlated with SLEDAI (r=0.74, p=0.014).

Conclusions mCD64 expression may be a potential biomarker for evaluating not only the disease activity but also the response of treatment in NPSLE.

Systemic lupus erythematosus (SLE) is the prototype of systemic autoimmune disorders.

Interferon alpha is a pleiotropic cytokine that can affect multiple cell types involved in lupus.

Dendritic cells (DC) have a special role in the production of IFN and are the main sources of serum interferon. IFN has the potential to dramatically influence the development, progression, and pathogenesis of SLE as it can influence the function and activation state of most major immune cell subsets and function as a bridge between innate and adaptive immunity.

Circulating microparticles (MPs) are ubiquitous in the blood of healthy individuals. These MPs play an active role in coagulation and intercellular communication and assist in activation or suppression of the immune system, depending on their parental cell origin. Changes in the concentration and/or composition of circulating MPs have been described in various autoimmune diseases, including rheumatoid arthritis (RA) systemic sclerosis (SSc) and SLE.

For SLE, the reported microparticle-related changes remain somewhat inconclusive.

To better understand the role of MPs in SLE patients, we analysed the presence of IFN-alpha on MPs surface.

MPs were isolated from citrate-treated plasma; blood cells were removed by two steps of centrifugation process (2500 g for 15 min at 20 C two time). The resulting platelet-poor-plasma (PPP), was analysed by flow cytometry with specific antibody against IFN-alpha.

20 consecutive SLE patients (10 with active lupus nephritis) and 10 sex- and age-matched healthy control subjects (HC) were included in the study.

We found that MPs from SLE patients carry on their surface IFN alpha.

Moreover, the percentage IFNα+MPs was higher in SLE patients and in lupus nephritis patients than in HC, but there was not significant difference between patients with and without renal involvement.

The results of the present study show for the first time the presence of IFN-alpha on MPs surface.

We may assume that INF+MPs derive from DC. In lupus nephritis patients the increased recruitment of DC was at tubular interstitial level, with subsequent IFN-alpha production. Interestingly, MPs (containing RNA and DNA) could stimulate type 1 IFN production in plasmacytoid dendritic cells and subsequently the release of MPs from DC.
Background Systemic lupus erythematosus (SLE) is a disease characterised by auto-antibody production. A wide variety of antibodies to extractable nuclear antigens (ENA) and double-stranded DNA (dsDNA) are frequently observed. This study aimed to assess the clinical significance of these antibodies within a large lupus cohort across 40 years of follow-up, with particular importance placed upon progression and time to damage.

Methods A retrospective review of patient medical records from the University College London Hospital (UCLH) lupus clinic since inception in 1978 was performed. All patients were required to fulfil revised ACR criteria for a diagnosis of SLE. ENA (including anti-Ro, anti-La, anti-RNP, anti-Sm) and anti-dsDNA were recorded as positive if they had ever been found to be present. A variety of clinical manifestations were recorded. Furthermore, the time from diagnosis to the first onset of SLICC criteria damage was measured. Statistical analysis was performed using chi squared and Student’s t test with a p-value<0.05 felt to be statistically significant.

Results A total of 170 patients were identified (mean age at diagnosis was 30 years old; 93% female; mean follow-up time was 22 years). 139 (82%) had sustained damage, and 54 (32%) had died. 59% (100/170) were anti-dsDNA positive, 13% (22/170) were anti-Sm positive, 28% (47/170) were anti-RNP positive, 38% (64/170) were anti-Ro positive, and 12% (20/170) were anti-La positive. There was a significant association between anti-dsDNA positivity and developing damage (see table 1). There was no difference in mean time to damage for all antibodies analysed. These antibodies did not show significant association with death. Anti-dsDNA positivity associated with renal damage (p<0.0001), and there was a statistically significant association between anti-Sm positivity and alopecia (p=0.049).

Conclusion Within this large lupus cohort followed up over 40 years, a significant association between anti-dsDNA and damage is observed. No association was found between antibody positivity and death, or time to damage.

Abstract PS2:34 Table 1

<table>
<thead>
<tr>
<th></th>
<th>Damage</th>
<th>Death</th>
<th>Mean time to damage (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-dsDNA positive (n=100)</td>
<td>87</td>
<td>31</td>
<td>139</td>
</tr>
<tr>
<td>Anti-dsDNA negative (n=70)</td>
<td>52</td>
<td>23</td>
<td>154</td>
</tr>
<tr>
<td>p</td>
<td>0.035</td>
<td>0.79</td>
<td>0.98</td>
</tr>
<tr>
<td>Anti-Ro positive (n=64)</td>
<td>55</td>
<td>16</td>
<td>145</td>
</tr>
<tr>
<td>Anti-Ro negative (n=106)</td>
<td>84</td>
<td>38</td>
<td>145</td>
</tr>
<tr>
<td>p</td>
<td>0.27</td>
<td>0.14</td>
<td>0.09</td>
</tr>
<tr>
<td>Anti-La positive (n=20)</td>
<td>18</td>
<td>6</td>
<td>184</td>
</tr>
<tr>
<td>Anti-La negative (n=150)</td>
<td>121</td>
<td>48</td>
<td>139</td>
</tr>
<tr>
<td>p</td>
<td>0.31</td>
<td>0.86</td>
<td>0.66</td>
</tr>
<tr>
<td>Anti-Sm positive (n=22)</td>
<td>17</td>
<td>5</td>
<td>134</td>
</tr>
<tr>
<td>Anti-Sm negative (n=122)</td>
<td>122</td>
<td>49</td>
<td>146</td>
</tr>
<tr>
<td>p</td>
<td>0.56</td>
<td>0.12</td>
<td>0.21</td>
</tr>
<tr>
<td>Anti-RNP positive (n=47)</td>
<td>42</td>
<td>14</td>
<td>127</td>
</tr>
<tr>
<td>Anti-RNP negative (n=123)</td>
<td>97</td>
<td>40</td>
<td>152</td>
</tr>
<tr>
<td>p</td>
<td>0.11</td>
<td>0.73</td>
<td>0.45</td>
</tr>
</tbody>
</table>

Introduction Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide spectrum of manifestations. Disease severity and outcome are variable in different ethnic groups. The aim of this study was to describe clinical, biological and immunological features of SLE in a Tunisian cohort.

Objectives A retrospective study, including patients with SLE (Revised criteria of the American College of Rheumatology), followed in a department of Internal Medicine from 2004 to 2017. Demographic, clinical, biological and immunological characteristics of patients were recorded and analysed. Treatment and outcome were described.

Results Medical records of 89 patients were analysed. Their mean age at the disease onset was 35.2 years±13 years (14 to 72 years). F/M sex ratio was 8/1. Familiar history of SLE or another autoimmune disease was recorded in 5.6% and 10.1% of patients respectively. Clinical manifestations were as following: cutaneous involvement in 88.8%, pulmonary manifestations in 23.6%, cardiovascular involvement in 43.8%, renal involvement in 29.2%, articular manifestations in 69.7%.